Pernix Therapeutics to Report Second Quarter 2012 Financial Results on August 14, 2012

Pernix Therapeutics to Report Second Quarter 2012 Financial Results on August 14, 2012

Pernix Therapeutics Holdings, Inc.Joseph T. Schepers, Director, Investor Relations, 800-793-2145 ext. 3002

Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2012 financial results before the U.S. stock market opens on Tuesday, August 14, 2012 and has scheduled a conference call at 9:00 am EDT that day to discuss the financial results.

The conference call will feature remarks by Cooper Collins, Chief Executive Officer, and David Becker, Chief Financial Officer. To participate in the conference call, please dial (877) 874-1565 (domestic) or (719) 325-4751 (international). Participants can reference the passcode 4635735. Please dial in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, . Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast.

A replay of the conference call will be available through August 21, 2012, at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for the replay is 4635735. An online archive of the webcast will be available on the Company's website for 30 days following the call.

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded and generic products. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of prescription treatments for cough and cold (BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for the gastroenterology market include OMECLAMOX-PAK®, a ten-day therapy of omeprazole delayed-release capsules, clarithromycin tablets and amoxicillin capsules for the treatment of Helicobacter pylori infection and duodenal ulcer disease and REZYST™, a probiotic blend to promote dietary management. The Company promotes its branded pediatric products through its sales force. Pernix also markets generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. A product candidate utilizing cough-related intellectual property, is in development for the U.S. OTC market. Founded in 1996, the Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website located at .